Prevalence
Clinical
features
Differential
diagnosis
Investigations
Therapy
Prevention
Prognosis
|  |  | | Therapy |
Give a low molecular weight heparin (LMWH)
a
(e.g. tinzaparin 175 units/kg
subcutaneously) whilst waiting for the results of investigations.
No monitoring is necessary for LMWH.
d
Why?
-
It is more effective than unfractionated heparin.
a
-
It causes fewer bleeds than unfractionated heparin.
a
-
It is as more cost-effective than intravenous unfractionated heparin.
a
LMWH and warfarin reduces death and causes less bleeding than heparin and warfarin
| Patient |
Treatment |
Comparison |
Outcome |
CER |
OR (95% CI) |
NNT
(95% CI) |
venous thromboembolism
a
|
LMWH and warfarin
|
heparin and warfarin
|
death
at
3-6
months
|
5.7%
|
0.74 (0.57 to
0.98) |
59
(35 to
780)
|
|
|
|
|
major bleed
at
3-6
months
|
2.0%
|
0.55 (0.34 to
0.89) |
115
(78 to 472)
|
cancer and venous thromboembolism
a
|
LMWH and warfarin
|
heparin and warfarin
|
death
at
3-6
months
|
24%
|
0.53 (0.33 to
0.85) |
10
(7 to
35)
|
|